Translate page

ERSAP Preceptorship Program

 

ERSAP Clinical Preceptorship Program 2014 open for applications

 

The Emerging Regions Support and Partnership (ERSAP) Clinical Preceptorship Program 2014 is now open for applications. The intention of this educational program is to enhance the knowledge of physicians treating patients with CML in emerging regions. Preceptorships combine practical experience, one-to-one tuition, seminars and laboratory work.

The 2013 ERSAP Clinical Preceptorship Program is now open for applications

 

The iCMLf is pleased to announce that the 2013 ERSAP Clinical Preceptorship Program is open for applications. These educational preceptorships are designed for clinicians from emerging economic regions with a specific interest in the treatment of CML and a significant CML patient load. The program enhances clinical knowledge and skills in the treatment of CML through 3 to 4 week preceptorships at internationally renowned CML centres. The program application form and overview brochure are available for download now. Alternatively contact melissa@cml-foundation.org for further information. Applications close on the 17th December 2012.

 

ERSAP Preceptorship Program continuing in 2013

 

Applications for the 2013 program are now open and we still have many countries to reach so please share the information about this preceptorship program with colleagues who may benefit. Completed application forms should be emailed to melissa@cml-foundation.org.

 

This program is designed for clinicians from emerging economic regions with a specific interest in the treatment of CML and a significant CML patient load. The program enhances clinical knowledge and skills in the treatment of CML through preceptorships at internationally renowned CML centres.


Participants are part of the clinical team at the host site for the duration of the preceptorship, undertaking seminars and laboratory work where appropriate.  Through this practical application of learning, clinicians attending the preceptorship have the opportunity to develop and enhance clinical knowledge to take back and share with colleagues in their country of origin. The programs are 'no profit' for the specialist CML centres, which donate their staff and resources to facilitate the program. More information about the ERSAP Clinical Preceptorship Program can be found in the program brochure.


About to start its forth year, the ERSAP Clinical Preceptorship Program is having a positive impact in the treatment of CML across emerging economic regions. Feedback from preceptors has confirmed that the goals of the program are being met, indicating improved knowledge and plans to share this with colleagues at home. Preceptors form collaborations with the host centre and many are undertaking further research projects. 

 

The following comments are examples of this feedback:

  • "It was an honor and a pleasure to have participated in this training, despite the vast difference between these institutions and hospitals in developing countries. It is certain that all is not feasible to us but we can certainly learn to improve our management." -- TH Madagascar
  • "…it was very useful to learn both the clinical and laboratory aspects of Quantitative BCR ABL and I think this will certainly improve the management of our patients." -- RS Pakistan
  • "…I have clarity in my mind on how to proceed with management of patients who become resistant to first line tyrosine kinase inhibitors and even those who are resistant to second-line TKIs." -- PM India

 

Selection Criteria & Application Process for Participants

The iCMLf seeks to improve the resources and knowledge of physicians treating patients with CML in emerging regions. The iCMLf will select up to 30 hematologists for the program whose attendance is expected to provide most benefit in this CML community. Candidates should have a special interest in CML management and be able to demonstrate their ability to apply and disseminate to colleagues knowledge gained from the program.

 

Preceptorship Program Content

Through one-on-one tuition and hands-on experience, participants will conclude the program with a practical understanding of the latest information influencing the care of patients with CML. This will include:
• therapies to treat CML; efficacy, toxicity and the management of side effects
• monitoring guidelines
• management of resistance
• role of allograft in CML
• developments in novel therapies, vaccines and drug cessation

The preceptorships are designed as an interactive process with participants steering their own education throughout the program.

Participating Centers of the 2013 Clinical Preceptorship Program

Preceptorships will take place at eleven designated international specialist CML centres and last for 3-4 weeks. Host sites include English, French, Italian, Russian and Spanish speaking centres.

Find detailed descriptions of the participating centers here.

More Information & Application Form

Download the documents of the 2013 ERSAP Clinical Preceptorship Program: